Epstein–Barr virus and inflammatory bowel disease: a systematic review of its clinical significance and potential pathogenic role
Inflammatory Bowel Diseases · 2026-11-10
DOI: 10.1093/ibd/izag230 ↗Abstract
Abstract Background Several studies report an association between Epstein–Barr virus (EBV) and inflammatory bowel disease (IBD). This review critically synthesizes current evidence on these association between EBV and IBD, its potential mechanisms, clinical implications, and research gaps. Methods A systematic search identified studies investigating EBV in IBD using serological, molecular, and tissue-based approaches. Data on EBV prevalence, viral load, disease phenotype, treatment status, and clinical outcomes were extracted, and study quality was assessed. A narrative review examined proposed mechanisms that may potentially link EBV to intestinal inflammation. Results From 7271 citations, 45 studies met inclusion criteria. EBV was more frequently detected in intestinal tissue from IBD patients than in controls, particularly in active or refractory disease, whereas findings for seroprevalence and blood-based markers were less consistent. Some longitudinal studies reported associations between prior EBV exposure and subsequent IBD, particularly Crohn’s disease, but these observations do not establish a causal relationship. Proposed mechanisms involving EBV-infected B cells, molecular mimicry, and altered cytokine signaling provide biological plausibility but remain unproven in IBD. EBV latency programs and age at seroconversion may influence disease progression and reactivation risk, although data remain limited. Corticosteroids and therapy with infliximab plus azathioprine have been associated with higher EBV loads, especially in refractory disease, yet these findings may be confounded by disease severity and treatment exposure. Conclusions Current evidence supports an association between EBV and IBD, particularly in severe and refractory disease but does not establish—and equally does not exclude—a pathogenic role for EBV. Considerable methodological heterogeneity in study design and EBV detection methods and the observational nature of the available data limit causal interpretation. Prospective mechanistic studies are needed to determine whether EBV is a causal contributor, a disease modifier, or a marker of underlying immune dysregulation.
EUVIMED